Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;41(10):853-854.
doi: 10.1016/j.it.2020.08.003. Epub 2020 Aug 11.

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2

Shibo Jiang  1 , Lanying Du  2
Affiliations
Comment

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2

Shibo Jiang et al. Trends Immunol. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential Effects of Low Pathogenic Human Coronavirus (LPH-CoV)-Specific Antibodies (Abs) on Infectivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 first binds to a cellular receptor, such as angiotensin-converting enzyme 2 (ACE2), on the target cells through its receptor-binding domain (RBD) in the S1 subunit of the spike (S) protein, which triggers the conformational change of the S2 subunit, resulting in virus–cell membrane fusion and viral entry into to the target cells for replication. (A) LPH-CoV-specific Abs may bind to S1 (in some cases) or S2 of SARS-CoV-2 S protein to block receptor binding or inhibit membrane fusion and entry into the target cells. (B) LPH-CoV-specific Abs with no, or low-titer, neutralizing activity against SARS-CoV-2 may also enter the host cells by binding to Fc receptor (FcR) on the cell membrane, resulting in antibody-dependent enhancement (ADE) effect on SARS-CoV-2 infection. This figure was created using BioRender (https://biorender.com/).
See this image and copyright information in PMC

Comment on

References

    1. Wang N. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 2020;11:298. - PMC - PubMed
    1. Ma Z. Does cross-neutralization of SARS-CoV-2 only relate to high pathogenic coronaviruses. Trends Immunol. 2020;41 doi: 10.1016/j.it.2020.08.002. - DOI - PMC - PubMed
    1. Tai W. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antivir. Res. 2020;179:104820. - PMC - PubMed
    1. Pinto D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–295. - PubMed
    1. Wang C. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020;11:2251. - PMC - PubMed